Multiple Sclerosis Clinical Trial
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Summary
The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.
Eligibility Criteria
Inclusion Criteria:
Adult male or female aged 18-55 years inclusive at screening
Patients who have a definite diagnosis of relapsing-remitting Multiple Sclerosis
Exclusion Criteria:
Multiple Sclerosis course other than relapsing-remitting multiple sclerosis
History of malignancy
History of clinically significant chronic disease of the immune system (other than Multiple Sclerosis)
Inability to undergo Gd-enhanced MRI scans
Diagnosis of diabetes mellitus (type I or type II)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 72 Locations for this study
Tucson Arizona, 85741, United States
Aurora Colorado, 80045, United States
Fort Collins Colorado, 80528, United States
Fairfield Connecticut, 06824, United States
Ormond Beach Florida, 32174, United States
Sarasota Florida, 34243, United States
Sarasota Florida, 34243, United States
Northbrook Illinois, 60062, United States
Fort Wayne Indiana, 46805, United States
Indianapolis Indiana, 46202, United States
Detroit Michigan, 48202, United States
Farmington Hills Michigan, 48334, United States
Lebanon New Hampshire, 03756, United States
Albuquerque New Mexico, 87131, United States
Rochester New York, 14642, United States
Charlotte North Carolina, 28204, United States
HighPoint North Carolina, 27265, United States
Raleigh North Carolina, 27607, United States
Akron Ohio, 44320, United States
Philadelphia Pennsylvania, 19104, United States
Knoxville Tennessee, 37934, United States
Round Rock Texas, 78681, United States
Seattle Washington, 98101, United States
Brugge , 8000, Belgium
La Louviere , 7100, Belgium
Sijsele , 8340, Belgium
Gatineau Quebec, , Canada
Greenfield Park Quebec, J4V2J, Canada
British Columbia , V6T 2, Canada
Quebec , H1T 2, Canada
Quebec , H9X 3, Canada
Olomouc , 775 2, Czech Republic
Ostrava , 702 0, Czech Republic
Pardubice , 532 0, Czech Republic
Praha 5 , 150 0, Czech Republic
Berlin , 13347, Germany
Essen , 45147, Germany
Giessen , 35385, Germany
Leipzig , 04103, Germany
Mainz , 55101, Germany
Marburg , 35033, Germany
Munster , 48149, Germany
Tubingen , 72076, Germany
Ulm , 89081, Germany
Athens , 11529, Greece
Thessaloniki , 57010, Greece
Kanto , , Japan
Kanto , , Japan
Kanto , , Japan
Kanto , , Japan
Kinki , , Japan
Kinki , , Japan
Kinki , , Japan
Tohoku , , Japan
Tohoku , , Japan
Bialystok , 15-40, Poland
Czeladz , 41-25, Poland
Gdansk , 80-80, Poland
Katowice , 40-59, Poland
Krakow , 31-53, Poland
Lodz , 90-15, Poland
Plewiska , 62-06, Poland
Warszawa , 04-74, Poland
Chelyabinsk , 45413, Russian Federation
Kaluga , 42800, Russian Federation
Kazan , 42010, Russian Federation
Moscow , 10715, Russian Federation
Nizhniy Novgorod , 60315, Russian Federation
Novosibirsk , 63009, Russian Federation
Samara , 44309, Russian Federation
St. Petersburg , 42800, Russian Federation
St. Petersburg , 42800, Russian Federation
Ufa , 45000, Russian Federation
Yaroslavl , 15003, Russian Federation
Barcelona , 08025, Spain
Barcelona , 08025, Spain
Bilbao , 48013, Spain
Girona , 17007, Spain
Hospitalet de Llobregat , 08907, Spain
Sevilla , 41071, Spain
Dnipropetrovsk , 49027, Ukraine
Donetsk , 83000, Ukraine
Kharkiv , 61068, Ukraine
Kyiv , 03110, Ukraine
Lviv , 79010, Ukraine
Vinnytsya , 21005, Ukraine
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.